X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1293) 1293
Publication (150) 150
Book Review (45) 45
Book Chapter (15) 15
Book / eBook (6) 6
Newsletter (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1058) 1058
index medicus (773) 773
monoclonal gammopathy (737) 737
multiple myeloma (571) 571
hematology (495) 495
male (427) 427
female (401) 401
undetermined significance (400) 400
oncology (383) 383
middle aged (381) 381
aged (344) 344
multiple myeloma - drug therapy (225) 225
prognosis (222) 222
adult (219) 219
multiple-myeloma (213) 213
multiple myeloma - pathology (197) 197
cancer (162) 162
multiple myeloma - diagnosis (158) 158
treatment outcome (158) 158
multiple myeloma - genetics (155) 155
stem-cell transplantation (154) 154
aged, 80 and over (141) 141
diagnosis (141) 141
care and treatment (140) 140
bone marrow (131) 131
risk factors (130) 130
multiple myeloma - therapy (126) 126
antineoplastic agents - therapeutic use (120) 120
research (118) 118
immunoglobulins (116) 116
disease progression (110) 110
therapy (109) 109
animals (106) 106
monoclonal gammopathy of undetermined significance (103) 103
health aspects (102) 102
survival (102) 102
bortezomib (99) 99
myeloma (98) 98
antineoplastic combined chemotherapy protocols - therapeutic use (97) 97
analysis (94) 94
hematology, oncology and palliative medicine (94) 94
patients (90) 90
rituximab (89) 89
disease (88) 88
monoclonal antibodies (87) 87
multiple myeloma - immunology (87) 87
multiple myeloma - metabolism (85) 85
medicine & public health (84) 84
chemotherapy (83) 83
development and progression (83) 83
medicine, general & internal (83) 83
gammopathy (81) 81
proteins (81) 81
monoclonal gammopathy of undetermined significance - diagnosis (80) 80
article (79) 79
monoclonal gammopathy of undetermined significance - complications (79) 79
risk (79) 79
immunology (78) 78
clinical neurology (77) 77
retrospective studies (77) 77
expression (75) 75
transplantation (75) 75
monoclonal gammopathies (74) 74
multiple myeloma - complications (74) 74
review (74) 74
diagnosis, differential (73) 73
progression (73) 73
monoclonal gammopathy of undetermined significance - drug therapy (72) 72
undetermined significance mgus (70) 70
antibodies, monoclonal - therapeutic use (69) 69
bone-marrow (67) 67
leukemia (67) 67
long-term (67) 67
lymphomas (66) 66
bone marrow - pathology (64) 64
paraproteinemias - complications (64) 64
biopsy (63) 63
stem cells (63) 63
medical research (62) 62
plasma cells (62) 62
genetic aspects (61) 61
mgus (61) 61
multiple myeloma - mortality (61) 61
thalidomide (61) 61
amyloidosis (60) 60
neurosciences (60) 60
dexamethasone (59) 59
peripheral neuropathy (59) 59
chronic lymphocytic-leukemia (58) 58
flow cytometry (58) 58
multiple myeloma - blood (58) 58
drug therapy (57) 57
immunotherapy (56) 56
internal medicine (56) 56
pathology (56) 56
medicine (55) 55
paraproteinemias - diagnosis (55) 55
abridged index medicus (54) 54
high-dose therapy (54) 54
pathogenesis (54) 54
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1261) 1261
French (15) 15
Japanese (9) 9
Spanish (9) 9
German (8) 8
Danish (2) 2
Italian (2) 2
Norwegian (2) 2
Polish (2) 2
Arabic (1) 1
Czech (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Annals of the New York Academy of Sciences, ISSN 0077-8923, 01/2016, Volume 1364, Issue 1, pp. 32 - 51
Multiple myeloma (MM) is a B cell malignancy resulting in osteolytic lesions and fractures. In the disease state, bone healing is limited owing to increased... 
multiple myeloma | Fairfield, H., C. Falank, L. Avery & M. R. Reagan. 2016. Multiple myeloma in the marrow: pathogenesis and treatments. In “MARROW,” ed. by M. Zaidi. Ann. N.Y. Acad. Sci. 1364: 32–51 | treatments | bone marrow | bone marrow niche | Bone marrow | Bone marrow niche | Treatments | Multiple myeloma | PEGYLATED LIPOSOMAL DOXORUBICIN | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | AUTOLOGOUS TRANSPLANTATION | MESENCHYMAL STEM-CELLS | PLASMA-CELLS | RANDOMIZED PHASE-III | ENDOCRINOLOGY & METABOLISM | MONOCLONAL GAMMOPATHY | OSTEOLYTIC BONE-DISEASE | LOW-DOSE DEXAMETHASONE | LENALIDOMIDE MAINTENANCE | Monoclonal Gammopathy of Undetermined Significance - drug therapy | Monoclonal Gammopathy of Undetermined Significance - genetics | Humans | Antineoplastic Agents - therapeutic use | Neoplasm Proteins - metabolism | Bone Remodeling - drug effects | Multiple Myeloma - therapy | Bone Marrow - metabolism | Monoclonal Gammopathy of Undetermined Significance - metabolism | Bone Marrow Cells - drug effects | Neoplasm Proteins - genetics | Bone Marrow - drug effects | Tumor Microenvironment - drug effects | Stem Cell Niche | Bone Marrow Cells - cytology | Bone Marrow Cells - pathology | Transplantation, Autologous - trends | Multiple Myeloma - metabolism | Multiple Myeloma - pathology | Animals | Monoclonal Gammopathy of Undetermined Significance - pathology | Tumor Burden - drug effects | Models, Biological | Bone Marrow - pathology | Precision Medicine - trends | Stem Cell Transplantation - trends | Mutation | Bone Marrow Cells - metabolism | Multiple Myeloma - genetics | Development and progression | Therapeutics | Homeopathy | Materia medica and therapeutics | Disease | Pathogenesis | Mutations | Progressions | Biomedical materials | Biocompatibility | Bones | Tumors
Journal Article
Journal Article
Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2016, Volume 91, Issue 5, pp. 473 - 475
Journal Article
Integrative Cancer Therapies, ISSN 1534-7354, 6/2016, Volume 15, Issue 2, pp. 183 - 189
Journal Article
Neoplasia, ISSN 1476-5586, 01/2019, Volume 21, Issue 1, pp. 93 - 105
Interactions of multiple myeloma (MM) cells with endothelial cells (ECs) enhance angiogenesis and MM progression. Here, we investigated the role of Notch... 
DLL4 | SIGNALING PATHWAYS | ONCOLOGY | VEGF | ENDOTHELIAL-CELLS | BONE-MARROW | MONOCLONAL GAMMOPATHY | PROLIFERATION | JAGGED1 | EXPRESSION | INHIBITS TUMOR-GROWTH | Immunohistochemistry | Propionates - pharmacology | Monoclonal Gammopathy of Undetermined Significance - drug therapy | RNA, Small Interfering - genetics | Receptors, Notch - metabolism | Humans | Receptors, Notch - genetics | Vascular Endothelial Growth Factor A - metabolism | Sulfones - pharmacology | Multiple Myeloma - drug therapy | RNA Interference | Monoclonal Gammopathy of Undetermined Significance - metabolism | Benzene Derivatives - pharmacology | Disease Models, Animal | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Multiple Myeloma - metabolism | Xenograft Model Antitumor Assays | Multiple Myeloma - pathology | Animals | Monoclonal Gammopathy of Undetermined Significance - pathology | Signal Transduction - drug effects | Cell Line, Tumor | Neovascularization, Pathologic - genetics | Mice | Neovascularization, Pathologic - metabolism | Multiple Myeloma - genetics | Phenotypes | Leukocyte migration | Cytokines | Secretion | Therapeutic applications | Multiple myeloma | Monoclonal gammopathy | Gammopathy | Inflammation | Chemotaxis | Endothelial cells | Angiogenesis | Jagged1 protein | Vascular endothelial growth factor | Secretase | Cell migration
Journal Article
British Journal of Haematology, ISSN 0007-1048, 02/2007, Volume 136, Issue 3, pp. 393 - 399
Journal Article